Akunne H C, Reid A A, Thurkauf A, Jacobson A E, de Costa B R, Rice K C, Heyes M P, Rothman R B
Unit on Receptor Studies, NIDDK, NIMH, Bethesda, Maryland 20892.
Synapse. 1991 Aug;8(4):289-300. doi: 10.1002/syn.890080407.
Previous work demonstrated two high-affinity PCP binding sites in guinea pig brain labeled by [3H]TCP (1-(1-[2-thienyl]cyclohexyl)piperidine): site 1 (N-methyl-D-aspartate [NMDA]-associated) and site 2 (dopamine-reuptake complex associated). The present study examined brain membranes prepared from various species, including human, for the presence of site 2, defined as binding in the presence of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a, d]cyclohepten-5,10-imine maleate ((+)-MK801) minus binding in the presence of 10 microM TCP (nonspecific binding). Studies were conducted in absence of sodium which was found to be inhibitory to [3H]TCP binding. The results demonstrated detectable levels of site 2 in brain membranes of guinea pig, rabbit, pig, mouse, sheep, and human but not in the rat or chicken. Using human cortical membranes, site 2 was the predominant binding site. Detailed studies conducted with human cortical tissue showed that high-affinity dopamine (1-[2- [bis(4-fluorophenyl)-methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909)], [1,2]benzo(b)thiophenylcyclo-hexylpiperidine (BTCP), and serotonin (fluoxetine) uptake inhibitors produced a wash-resistant inhibition of [3H]TCP binding to site 2, but not site 1. Preincubation of guinea pig brain membranes with BTCP was shown to produce an increase in the dissociation rate of [3H]TCP from PCP site 2. Structure activity studies with various uptake inhibitors showed that GBR12909, benztropine, fluoxetine, and BTCP have higher affinity for site 2 than for site 1. (+)-MK801, ketamine, and tiletamine were very selective for site 1, whereas dexoxadrol and TCP were moderately selective for site 1. These results suggest that human cortex possesses high-affinity PCP binding sites associated with biogenic reuptake binding sites, and that guinea pig brain, but not rat brain, may be an appropriate animal model for studying PCP site 2 in human brain.
先前的研究表明,豚鼠脑中存在两个由[3H]TCP(1-(1-[2-噻吩基]环己基)哌啶)标记的高亲和力PCP结合位点:位点1(与N-甲基-D-天冬氨酸[NMDA]相关)和位点2(与多巴胺再摄取复合物相关)。本研究检测了包括人类在内的各种物种制备的脑膜中是否存在位点2,其定义为在(+)-5-甲基-10,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺马来酸盐((+)-MK801)存在下的结合减去在10 microM TCP存在下的结合(非特异性结合)。研究在无钠的条件下进行,发现钠对[3H]TCP结合有抑制作用。结果表明,豚鼠、兔、猪、小鼠、绵羊和人类的脑膜中可检测到位点2的水平,但大鼠或鸡的脑膜中未检测到。使用人类皮质脑膜时,位点2是主要的结合位点。对人类皮质组织进行的详细研究表明,高亲和力多巴胺(1-[2-[双(4-氟苯基)-甲氧基]乙基]-4-(3-苯基丙基)哌嗪(GBR12909)]、[1,2]苯并(b)噻吩基环己基哌啶(BTCP)和5-羟色胺(氟西汀)摄取抑制剂对[3H]TCP与位点2的结合产生耐洗脱抑制作用,但对位点1无此作用。用BTCP预孵育豚鼠脑膜可使[3H]TCP从PCP位点2的解离速率增加。对各种摄取抑制剂的构效关系研究表明,GBR12909、苯海索、氟西汀和BTCP对位点2的亲和力高于位点1。(+)-MK801、氯胺酮和替来他明对位点1具有高度选择性,而地佐环醇和TCP对位点1具有中等选择性。这些结果表明,人类皮质具有与生物源性再摄取结合位点相关的高亲和力PCP结合位点,并且豚鼠脑而非大鼠脑可能是研究人类脑中PCP位点2的合适动物模型。